View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Occidental Announces Total Consideration for its Cash Tender Offers an...

Occidental Announces Total Consideration for its Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the consideration payable in respect of its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its Zero Coupon Senior Notes due 2036 (the “0.000% 2036 Notes”), 6.125% Senior Notes due 2031 (the “6.125% 2031 Notes”), 6.625% Senior Notes due 2030 (the “6.625% 2030 Notes”), 7.200% Debentures due 2029 (the “7.200% 2029 Debentures”) and 7.950% D...

 PRESS RELEASE

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presenta...

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human...

 PRESS RELEASE

Occidental Announces Early Tender Results and Upsize in Cash Tender Of...

Occidental Announces Early Tender Results and Upsize in Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the early tender results, as set forth in the table below, of its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its Zero Coupon Senior Notes due 2036 (the “0.000% 2036 Notes”), 6.125% Senior Notes due 2031 (the “6.125% 2031 Notes”), 6.625% Senior Notes due 2030 (the “6.625% 2030 Notes”), 7.200% Debentures due 2029 (the “7.200% 2...

 PRESS RELEASE

Texas Capital Earns Best Bank Award for Middle Market Banking in the U...

Texas Capital Earns Best Bank Award for Middle Market Banking in the U.S. (West) Clients cite strong satisfaction with the firm’s middle market banking DALLAS, March 03, 2026 (GLOBE NEWSWIRE) -- Texas Capital announced today that it has been named as a Best Bank – Likelihood to Recommend for Middle Market Banking in the U.S. (West) by Crisil Coalition Greenwich, recognizing the firm’s approach to serving middle market companies through its client-focused, full-service banking platform. Texas Capital serves small business, middle market and corporate clients across industries and geogra...

Moody's Ratings assigns B1 rating to Matador's proposed senior unsecur...

Moody's Ratings (Moody's) assigned a B1 rating to Matador Resources Company's ("Matador") proposed $750 million senior unsecured notes due 2034. Matador's other ratings, including its Ba3 corporate family rating ("CFR") and stable outlook, remain unchanged. The net proceeds from this debt issuance...

 PRESS RELEASE

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial...

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 25, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Li...

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET. A live webcast of the ...

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong

The Week Ahead in Life Sciences

Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 19, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Hubbell Inc: 1 director

A director at Hubbell Inc sold after exercising options/sold 2,601 shares at 523.730USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

 PRESS RELEASE

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results...

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events”...

 PRESS RELEASE

Occidental Announces Cash Tender Offers and Consent Solicitations for ...

Occidental Announces Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced that it has commenced offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its outstanding senior notes and debentures listed in the table below and Consent Solicitations (as defined below) with respect to certain series of such senior notes and debentures, upon the terms and conditions described in Occidental’s Offer to Purchase and Consent Solicitation Statement, dated...

Terex Corp: 1 director

A director at Terex Corp sold 11,980 shares at 69.240USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Occidental Announces Fourth Quarter 2025 Results

Occidental Announces Fourth Quarter 2025 Results HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced its fourth quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the section of the company’s website at . The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Thursday, February 19, 2026, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (internat...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch